Clinical safety and efficacy of neoadjuvant combination chemotherapy of tranilast in advanced esophageal squamous cell carcinoma: Phase I/II study (TNAC)

BACKGROUND: Transient receptor potential vanilloid 2 (TRPV2) was previously shown to play an important role in the maintenance of cancer stem cells, and its specific inhibitor, tranilast, also has potential as a targeted therapeutic agent for esophageal squamous cell carcinoma (ESCC). The present st...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiozaki, Atsushi, Kudou, Michihiro, Fujiwara, Hitoshi, Konishi, Hirotaka, Shimizu, Hiroki, Arita, Tomohiro, Kosuga, Toshiyuki, Yamamoto, Yusuke, Morimura, Ryo, Ikoma, Hisashi, Kuriu, Yoshiaki, Kubota, Takeshi, Okamoto, Kazuma, Otsuji, Eigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
7100
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738016/
https://www.ncbi.nlm.nih.gov/pubmed/33327342
http://dx.doi.org/10.1097/MD.0000000000023633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738016/
https://www.ncbi.nlm.nih.gov/pubmed/33327342
http://dx.doi.org/10.1097/MD.0000000000023633

Ejemplares similares